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ABSTRACT  
Hepcidin is a polypeptide that regulates iron homeostasis and could serve as an indicator of functional iron 
deficiency in patients with end-stage renal disease (ESRD); this may also aid in the assessment of patient's 
response to erythropoietin (EPO). The present study was aimed to investigate serum levels of hepcidin, iron status 
and inflammation markers such as C-reactive protein (CRP) in patients with ESRD on maintenance HD and to 
observe the correlation of serum hepcidin with conventional iron and inflammatory markers.   
   A total of 59 patients  on maintenance HD were enrolled; 29 age and sex-matched healthy subjects were 
included as controls. Laboratory tests including complete blood count, creatinine, urea, albumin, BUN, serum 
hepcidin, serum ferritin, serum iron and CRP were performed. The serum hepcidin levels was measured  by a 
competitive enzyme-linked immunosorbent assay (C-ELISA). Serum hepcidin levels were significantly higher in 
patients with ESRD than in the control group (63.7± 47.4 ng/mL :11.5± 26.3 ng/mL respectively P<0.001). The 
hemoglobin and serum iron levels in the patient group were significantly lower than in the control group. Higher 
feritine levels were found in hemodialysis patients (448.5± 710 ng/mL): ( 98.3 ± 83 ng/mL) of controls (P =0.01). 
A positive and significant correlation was observed between the values of serum hepcidin and CRP.  Serum 
hepcidin and high-sensitivity C-reactive protein levels were significantly higher in maintenance haemodialysis 
patients ( case =21.2± 28.6 mg/L :control =2.9 ± 2.7 mg/L, P=0.001) .  
In conclusion, higher hepcidin levels are found in ESRD patients and serum hepcidin levels are associated with 
iron status and micro-inflammation (defined as hsCRP < 6mg/l, in maintenance haemodialysis patients). Also, our 
findings suggest that hepcidin might play a role in the pathophysiology of anemia associated with chronic diseases 
as ESRD. As well as, ELISA method for measuring serum hepcidin should facilitate the routine measurement of 
hepcidin in clinical practice. 
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INTRODUCTION      
     Anemia is commonly seen in all stages of renal disease but is much more obvious in patients with end-stage 
renal disease (ESRD).
1
  Patients with anemia due to chronic kidney disease (CKD) are at enlarged  risk of 
hospitalization, increased length of hospital stay, lower quality of life and higher mortality.
2
  The main causes of 
anemia in patients with CKD are chronic inflammation, decreased erythropoietin (EPO) production, iron 
deficiency, and  shortened half life of erythrocytes.
3
  Hepcidin is a peptide secreted by the liver that regulates 
plasma iron.
4
  Hepcidin production decreases in the presence of  hypoxia, iron deficiency, and ineffective 
erythropoiesis
5
, whereas increased production is stimulated by increased plasma and stored iron.
6
  Increased levels 
of hepcidin results in iron release in macrophages and decreased absorption of iron.
7
  Hepcidin production is also 
increased by inflammation and high hepcidin concentrations limit iron availability for erythropoiesis, thus playing 
a major role in the anemia of inflammation and EPO resistance.
8
 Hemodialysis (HD) is considered an 
inflammatory condition and increased serum hepcidin levels have been found in patients with ESRD on 
maintenance HD.
9
 These raise levels in hemodialyzed patients could be due to functional iron deficiency anemia 
and low-grade inflammation.
10
  Reticulo–endothelial blockade is seen during inflammation, which is mediated by 
hepcidin up-regulation, and results in inhibition of release of iron to transferring.
8,11
 Hepcidin also be part of the 
cause of  EPO resistance by regulating iron-restricted erythropoiesis and by its inhibitory effect on erythroid 
progenitor proliferation and continued existence.
8,11
  Uremia is a state of heightened inflammatory activation. This 
might have an impact on several parameters including those used in the management of anemia. Ferritin, for 
example, is a marker of body iron stores, but it also increases in acute inflammation and consequently becomes 
less valuable as an indicator of iron status during inflammation.
12
 Serum iron and transferrin saturation are also 
inclined by inflammation. Inflammation also increases the C-reactive protein (CRP) and hepcidin levels
9
  but in 
state  of this complexity the existing data indicate that hepcidin has an advantage over ferritin in guiding treatment 
of anemia in patients with CKD as it directly reflects iron availability and the status of iron homeostasis, better 
than other conventional parameters.
13
  The current study was designed to determine the values of these 
conventional markers of body iron stores, degree of inflammatory activation and serum hepcidin in patients with 
ESRD on maintenance HD and to compare them with normal controls.  
SUBJECTS AND LABORATORY METHODS 
Study Design and site:  A case control comparative study was conducted to achieve the objectives of the study. 
The study included 88 individuals aged 20-45 years old and they divided in to two groups: Group1: Consist of 59 
individuals who are end stage renal failure haemodialysis patients, we included only patients whom had 
maintenance haemodialysis for more than one year in nephrology and urology center in Al-Thawra University 
 Hospital- Sana'a City. Also pregnant women, patients with liver disease, and /or patients with Cardiovascular 
disease or any other chronic disease were excluded. Group 2:   Consist of 29 healthy individuals attending the 
same Hospital for routine examination (volunteers), who don't suffer from any other chronic diseases.   All 
Patients and controls  agree to fill  the written informed consent of the study. 
Data collecting: Data regarding demographic, clinical characteristics, body mass index (BMI), and duration of 
dialysis were recorded in predesigned forms for all patients, also demographic , clinical characteristics, and body 
mass index (BMI) were recorded in predesigned forms for all controls.  
Collection and storage of  blood  samples: Peripheral blood samples were collected in a vacationer tubes after 
an overnight fast, before a single session of haemodialysis for each patient. For controls  also peripheral blood 
samples were collected in a vacationer tubes after an overnight fast for each controls.  The whole blood samples 
were obtained using EDTA-tubes for measuring hematological markers for cases and controls. For serum Iron, 
serum ferritin, serum CRP and serum hepcidin 10 ml blood were collected in 10 ml capacity tubes containing Clot 
activator , then serum were separated by centrifuging,  and  stored in aliquots for cases and controls. Blood 
samples which occurred hemolysis would be discarded. Each serum  sample was given a tracking number and 
stored at − 20 °C until further analysis. 
Laboratory Tests: Hepcidin was tested in serum samples using manual enzyme-linked immunosorbent assay 
(ELISA) kit .  Ferritin was tested in serum samples using automated enzyme-linked immunosorbent assay (ELISA) 
system. The  tests were performed according to the manufacturer’s instructions described in the assay procedure. 
Blood Iron, CRP, albumin, creatinine were tested in the samples using automated system (integra 400 close 
system). Also. Hb and white blood cell count (WBC) were determined by automated procedures.   
Data analysis:  The analysis of data was done by Epi Info version 6 statistical program (CDC, Atlanta, USA), where 
the chi-square (χ2) and probability value (p) was calculated for the test of significance by comparing the geometric 
mean ± SD of the serum level of hepcidin, ferritin, iron and etc among cases (HD patients) comparing with that of 
healthy controls. In addition, Odd's ratio (OR), 95% confidence interval (95% CI) were added to estimate the 
associated OR for high level of hepcidin, ferritin and  iron etc. with HD patients comparing with that of healthy 
controls.  A p value < 0.05 was considered significant.    
Ethical approval 
We obtained written consent from all cases and controls. Assent was taken from participants before collecting the 
specimens. The study proposal was evaluated and approved by the Ethics Committee of Faculty of Medicine and 
Health Sciences, Sana'a University. 
RESULT 
HD patients were counting 59 patients, 37 of them were males and 22 were females. The unmatched healthy 
controls of study were counting 29 healthy unmatched in age and sex with the patient group. The control included 
17 males and 12 females.  The Mean±SD of the patient's ages was 28.3±6.4 years and their ages ranged from 20-
45 years, while the Mean±SD of the control's ages was 25±3.5 years and their ages ranged from 20-40 years. Also 
the  BMI (Kg/m
2
) Mean±SD  of patients was 18.2±3.8 kg/m
2
 lower than 24.1±2.83 kg/m
2
 of the healthy controls 
(table 1). Table 2 shows the serum hepcidin and conventional markers of Iron status and markers of inflammation 
(CRP, WBCs) in hemodialysis patients and controls. The serum hepcidin levels were significantly (p=<0.001) 
higher in patients with ESRD on HD (Mean±SD= 63.77±47.4 ng/ml) compared to lower level in controls 
(Mean±SD=11.5±26 ng/ml). The Hb levels were significantly (p=<0.001) lower in patients (Mean±SD=7.97±1.4 
g/dL)  compared with healthy controls level (Mean±SD=15.55±1.3g/dL). The serum Ferittin (ng/ml) levels were 
significantly (p=<0.001) higher in patients ( Mean±SD= 448.5±710 ng/ml)  as compared with healthy controls 
level (Mean±SD was 98.3±83ng/ml). The serum CRP levels were significantly (p=<0.001) higher in patients 
(Mean±SD = 21.3±28.6 mg/L)  as compared with healthy controls ( Mean±SD =2.9±2.7mg/L). However no 
significant variations were observed in Serum Iron level and WBCs for both patients and controls.  Table 3 shows 
the serum albumin and conventional markers of kidney function in hemodialysis patients and controls. All these 
markers were significantly (p=<0.001) abnormal in patients and normal in healthy controls (table 3). Table 4 
shows the association of high level of hepcidin with conventional markers of iron status and marker of 
inflammation (CRP) among hemodialysis patients. In HD patients the rate of high level of hepcidin was 62.7%. 
There was no association between high level of hepcidin and high level of ferritin,  but there was association with 
low level of Iron (OR=4.9)  with non-significant result (P=0.11). Also there is association between high level of 
hepcidin and positive CRP (OR=1.2) and this result was not statistical significant (p=0.76).  Table 5 shows the 
associated odds ratio of low level of serum iron, high level of serum hepcidin, high level of serum ferritin, and 
positive CRP, in hemodialysis patients comparing with healthy controls. The rate of high level of ferritin was 
37.3% in HD patients comparing with 13.7% in controls. There was association between high level of ferritin in 
HD patients with positive CRP (OR= 3.7, CI=1.5-12, p=0.02). In addition there was association between low 
level of iron and HD patients (OR=1.5, CI=1.3-1.8, p=0.037). Also the risk difference to develop low level of Iron 
in HD comparing with controls is 36 times (CI=25-46). The rate of positive CRP was 52.5% in HD patients 
comparing with 3.4% in controls. In addition there was association between positive CRP and  HD patients (OR= 
 31, CI=3.9 -243, p<0.001). Also the risk difference to develop positive CRP in HD comparing with controls is 46 
times and this difference ranged from not less than 32 and up to 61 times. The rate of high level of hepcidin was 
62.7% in HD patients comparing with 6.9% in controls. In addition there was association between high level of 
hepcidin and  HD patients (OR= 22.7, CI=4.9 - 104, p<0.001). Also the risk difference to develop high level of 
hepcidin in HD comparing with controls is 49 times and this difference ranged from not less than 34 and up to 65 
times.  Table 6 shows the comparison of high (> 6mg/l) and low (<6 mg/l) CRP levels in relation to age, gender 
and hemodialysis duration for patients. The mean + SD age of CRP positive patients was 33.4±5.8 years older 
than the mean + SD age of CRP negative patients (26.5±7.1 years). Therefore there is association between age 
growing and occurring of positive CRP and this result was significant (p<0.001). Also, when we considered sex 
of the patients, there was significant association between male patients and positive CRP (p<0.05), that is mean 
male patients have more possibility to develop CPR positive than female patients. What is more, when we 
considered duration of hemodialysis and positivity of CRP, there was association between longer duration of 
hemodialysis and positive CRP. The mean + SD duration of CRP positive patients was 4.9±0.6 years longer than 
the mean + SD duration of CRP negative patients (3.8±0.4 years), but this variation was not statistically 
significant (p=0.08). Therefore there is association between long duration and occurring of positive CRP but not 
significant due to small sample size of the current study. 
DISCUSSION 
Hepcidin is now acknowledged to be the main iron regulatory hormone. It is a 25-amino acid peptide exclusively 
synthesized by the liver, initially identified as part of a search for novel antimicrobial peptides.
14,15
  There was no 
indication that it had an additional role in iron metabolism until 2001, when mouse studies were published 
showing that hepatic hepcidin mRNA synthesis was induced by iron loading.
16,17
  Also, Hepcidin levels are 
regulated by iron status and erythropoietic activity.
18
  It is now well documented that hepcidin levels are reduced 
by anemia and hypoxia and increased by inflammation.
19 
 Renal anemia is considered a special form of anemia of 
inflammation .
20
 The present study focused on the levels of serum hepcidin in patients with ESRD on maintenance 
HD for at least one year and their levels were then compared with controls. 
    In the present study, the enzyme-linked immunosorbent assay (ELISA) method was used for the detection of 
serum hepcidin levels and found that the levels were significantly (p<0.001) higher in patients with ESRD on HD 
in which the hepcidin Mean±SD level was 63.77±47.4ng/ml as compared with healthy controls (Mean±SD 
=11.5±26ng/ml) (table 2). Similar results were also reported by Zille et al. 
21
 in which the hepcidin Mean±SD 
level was 18.2 ± 2.8 ng/ml as compared with healthy controls in which the hepcidin Mean±SD level was 8.1 ± 2.3 
ng/ml.
21
  In present study results hepcidin levels were six –fold higher in patients of hemodialysis than the healthy 
controls (table 2). Also when the high level rate of hepcidin with hemodialysis considered there was significant 
odds ratio of high level of hepcidin with hemodialysis equal to 22.7 times comparing with that of controls (table 
5). The current study result is higher than that reported by Jairam et al.
12
 and  Swinkels and Wetzels
13
 in which 
hepcidin levels were only two- to three-fold higher in patients with hemodialysis comparing with controls. The 
high levels of hepcidin in hemodialysis patients can be explained by the fact that there are limited excretion of 
hepcidin by kidney or by dialysis in patients lead to elevation of hepcidin which cause tissue iron overload and 
inflammation.
22
 
Among present study group of hemodialysis patients, a significant decreased levels of Hb was found in which Hb 
Mean±SD level was 7.97±1.4g/dl as compared with healthy controls (Mean±SD level=15.55±1.3g/dL, p<0.001) 
(table 2). However, in the current study  there was non-significant decreased levels of the serum iron in among 
patients (Mean±SD=142.88±65ng/ml) as compared with healthy controls (Mean±SD=159.6±64ng/ml, p=0.35) 
(table 2). The present study findings are similar to that reported by Yilmaz et al.
23
 in which they reported renal 
anemia in most hemodialysis patients but with significant decreased levels of the serum iron in the patients 
comparing with controls.  
   In the present study serum ferittin levels found to be significantly (p<0.001) higher in patients with ESRD on 
HD (448.5±710ng/ml) as compared with healthy controls (98.3±8.3ng/ml) (table 2) . These findings consistent to 
Yilmaz et al.
23
 in which elevated ferittin was seen in patients with CKD. High ferittin levels may be observed in 
this disease because of functional iron deficiency or reticulo–endothelial blockade. This commonly seen paradox 
of high serum ferittin has made it desirable to look for a substitute iron marker to predict better iron status of the 
patient.
24
 Various other studies also support that current markers of iron metabolism; like ferittin do not predict 
iron status effectively
24
 and that this conventional marker have certain limitations.
6
 The diagnosis of iron 
deficiency using this marker is unproductive, as it can be affected by variables such as age, sex, inflammation and 
nutritional factors. In another study, it was concluded that determining hepcidin concentrations together with 
conventional markers associated with iron metabolism improved the identification of patients with iron deficiency 
by 26.1%.
25
  
   In this study, CRP was measured as the conventional marker of inflammation and was found to be higher in 
patients than in controls, significantly (p<0.001) (21.3±28.6mg/dL: 2.9±2.7mg/dL) (table 2); and also positive 
CRP were found to be significantly correlated with high serum hepcidin (OR=31, p<0.001) (table 5). It is known 
 that hepcidin synthesis is induced by inflammation, a process that is mediated by IL-6. As CKD is considered an 
inflammatory state, this positive correlation was expected
26
 The present study results are comparable to other 
studies on patients with renal failure, which showed a correlation of  high hepcidin levels with positive CRP.
27
 
However, these results are different from the finding of Memoli
26
 and Tovbin
28
  in which no correlation was 
observed between hepcidin and CRP levels in CKD patients. This lack of correlation may be explained on the 
basis of differences in the half-lives of CRP and hepcidin.
28
 
When high level (> 6mg/l) comparison with low level  (<6 mg/l) of CRP in relation to hemodialysis in the current 
study, there was 52.5% of the patients had high (> 6mg/l) CRP level (table 6). This result is higher than that 
reported by Korevaar et al. 
29
  in which this prospective multicenter study on the impact of an HD session on CRP 
level showed an increase in CRP level in 25% of the patients during a dialysis session. Moreover, independent of 
the pre-dialysis CRP level, the change in CRP level during an HD session was associated with an increased 
mortality risk; an increase of 1 mg/L in CRP level was associated with a 9% raised mortality risk. The present 
study finding suggests that a 52.5% of our patient with an increase of CRP level will have a raised mortality risk 
than the low CRP level patients.  CRP is a marker of inflammation, which involves a number of complex 
processes that can be induced by any trauma or infection. As soon as the inflammatory stimulus has been 
eliminated, the CRP level declines. The increase in CRP level observed in the present study could have been the 
result of such acute trauma or infection or a response to the dialysis.  There was significant association between 
high CRP and older HD patients (<0.001) (table 6) in the present study, this is similar to that reported by Rashid 
et al. 
27
 in which the rate of positive CRP was higher in older ages of HD patients. Additionally, it has been 
reported that the occurrence of inflammation is higher in patients who were on dialysis for a longer time 
30
 but 
there was no significant association between CRP and length of dialysis in the current study (table 6). 
CONCLUSION 
Higher hepcidin levels are found in ESRD patients and serum hepcidin levels are associated with iron status and 
micro-inflammation (defined as hsCRP < 6mg/l, in maintenance haemodialysis patients). Also, our findings 
suggest that hepcidin might play a role in the pathophysiology of anemia associated with chronic diseases as 
ESRD. As well as, ELISA method for measuring serum hepcidin should facilitate the routine measurement of 
hepcidin in clinical practice. 
RECOMMENDATION 
 A extensive information of hepcidin regulation will provide us with original tools for differential diagnosis, 
therapeutic regimes and monitoring of disorders of iron metabolism particularly in HD patients. However, a lot 
remains to be revealed on the biology and function of hepcidin. Its signaling pathways are as up till now to be 
defined. Additional studies are needed to define accurately the hepcidin role in iron metabolism homeostasis and 
its efficacy in the diagnosis and treatment of iron disorders.  Also that more studies need to be performed 
regarding the role of ferritin in HD patients. Finally prospective studies are needed to confirm whether elevated 
serum hepcidin and ferritin predict HD anemia and its elevation is failure execration by dialysis, or is simply a 
secondary marker of metabolic abnormalities. 
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Table1: Demographic data of subjects included in the study 
 
parameters 
Subjects 
patients controls 
Number of subjects 59 29 
Males 37 17 
Females 22 12 
Age (years) 
Mean±SD;   
28.3±6.4  25±3.5  
Range of age (years) 
 
20-45 20-40 
BMI (Kg/m
2
) Mean±SD   18.2±3.8 24.1±2.83 
 
 
 
 
  
 
 
 
 
Table 2: Serum hepcidin and conventional markers of Iron status and markers of inflammation (CRP, WBCs) in 
hemodialysis patients and controls 
Biochemical Parameters 
Patients  
(mean + SD)   
Controls 
(mean + SD)   
P value 
Hb (g/dl) 7.97±1.4 15.55±1.3 <0.001 
Serum Iron (mg/dL) 142.88±1 159.6±64 0.35 
Serum Ferittin (ng/ml) 448.5±710 98.3±83 <0.001 
CRP (mg/L) 21.3±28.6 2.9±2.7 <0.001 
WBCs x10
3
 5.6±1.7 5.0±1.16 0.10 
Hepcidin (ng/ml) 63.77±47.4 11.5±26 
<0.001 
 
Hb=Hemoglobin 
CRP=C-reactive protein 
SD=Standard division 
 
Table 3: Serum albumin and conventional markers of kidney function in hemodialysis patients and controls 
Biochemical Parameters 
Patients  
(mean + SD)   
Controls 
(mean + SD)   
P  
Creatinine (mg/dl) 10.08±9.3 0.935±0.115 <0.001 
Urea  (mg/dL) 152.5±50.2 21.58±7.0 <0.001 
BUN (ng/ml) 72.15±22.7 10.3±2.8 <0.001 
Albumin (g/L) 34.7±4.5 43.15±2.47 <0.001 
 
BUN =Blood urea nitrogen 
SD=Standard division 
Table 4: The association of high level of hepcidin with conventional markers of iron status and marker of 
inflammation (CRP) among hemodialysis patients 
Biochemical 
parameters 
High level of 
hepcidin n=37 OR CI χ2 P  
No % 
Serum Ferritin (high 
level)  n=22 
12 54.5 0.5 0.19-1.7 1.1 0.31 
Iron µg/dl 
(Low level)  n=8 
7 87.5 4.9 0.5-42 2.5 0.11 
Hb (g/dl) anemic n=58 36 62% undefined 0.6 0.4 
Serum CPR (Positive) 
n=31 
20 64.5 1.2 0.4-3.3 0.09 0.76 
Total high rate of 
Hepcidin n=59 
37 62.7     
Serum Ferritin (high level); for male >275ng/ml; for female >204ng/ml. 
Serum Iron (low level); for male <59 mg/dL; for female < 37 mg/dL. 
Serum CPR Positive (>6mg/dL) 
OR          Odds ratio = Relative risk CI           Confidence intervals  χ 2          Chi-square = 3.9 or more significant p           Probability value 
= 0.05 or less  significant 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  Table 5: The associated odds ratio of low level of serum iron, high level of serum hepcidin, high level of serum 
ferritin, and positive CRP, in hemodialysis patients comparing with healthy controls. 
Biochemical 
parameters 
Patients n=59 Controls n=29 
OR CI χ2 P 
Risk 
difference No % No % 
Serum Ferritin 
(high level)   
22 37.3 4 13.7 3.7 1.5-12 5.2 0.02 
 
36(25-46) 
Iron µg/dl 
(Low level)   
8 13.6 0 0 1.5 1.3-1.8 4.3 0.037 
36(25-46) 
Serum CPR 
(Positive)  
31 52.5 1 3.4 31 3.9-243 20.2 <0.001 
46(32-61) 
High level of 
hepcidin 
37 62.7 2 6.9 22.7 4.9-104 24.5 <0.001 
49(34-65) 
 
OR          Odds ratio = Relative risk CI           Confidence intervals  χ 2          Chi-square = 3.9 or more significant 
 p           Probability value = 0.05 or less  significant 
 
 
Table 6: Comparison of high (> 6mg/l) and low (<6 mg/l) CRP levels in relation to age, gender and hemodialysis 
duration for patients. 
 
Parameters High CPR (>6mg/L)   Low CRP (<6mg/L)  P  
Age ( mean + SD)  33.4±5.8 years 26.5±7.1years <0.001 
Gender 
 
Male 23 14 <0.05 
Female 8 14 0.15 
Total 31 28 0.84 
Hemodialysis duration mean + 
SD 
4.9±0.6 years 3.8±0.4 years 
0.08 
 
 
